These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16720237)

  • 1. In vitro and in vivo evaluation of novel ligands for radioimmunotherapy.
    Chong HS; Milenic DE; Garmestani K; Brady ED; Arora H; Pfiester C; Brechbiel MW
    Nucl Med Biol; 2006 May; 33(4):459-67. PubMed ID: 16720237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging.
    Chong HS; Garmestani K; Bryant LH; Milenic DE; Overstreet T; Birch N; Le T; Brady ED; Brechbiel MW
    J Med Chem; 2006 Mar; 49(6):2055-62. PubMed ID: 16539394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands.
    Sun X; Wuest M; Weisman GR; Wong EH; Reed DP; Boswell CA; Motekaitis R; Martell AE; Welch MJ; Anderson CJ
    J Med Chem; 2002 Jan; 45(2):469-77. PubMed ID: 11784151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI.
    Chong HS; Song HA; Ma X; Milenic DE; Brady ED; Lim S; Lee H; Baidoo K; Cheng D; Brechbiel MW
    Bioconjug Chem; 2008 Jul; 19(7):1439-47. PubMed ID: 18564868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.
    Camera L; Kinuya S; Garmestani K; Wu C; Brechbiel MW; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
    J Nucl Med; 1994 May; 35(5):882-9. PubMed ID: 8176477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics.
    Chong HS; Garmestani K; Ma D; Milenic DE; Overstreet T; Brechbiel MW
    J Med Chem; 2002 Aug; 45(16):3458-64. PubMed ID: 12139456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins.
    Chappell LL; Ma D; Milenic DE; Garmestani K; Venditto V; Beitzel MP; Brechbiel MW
    Nucl Med Biol; 2003 Aug; 30(6):581-95. PubMed ID: 12900284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic comparative evaluation of 90Y-labeled bifunctional chelators for their use in targeted therapy.
    Chakravarty R; Chakraborty S; Dash A
    J Labelled Comp Radiopharm; 2014 Feb; 57(2):65-74. PubMed ID: 24678528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy.
    Kang CS; Sun X; Jia F; Song HA; Chen Y; Lewis M; Chong HS
    Bioconjug Chem; 2012 Sep; 23(9):1775-82. PubMed ID: 22881720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy.
    Chong HS; Ma X; Le T; Kwamena B; Milenic DE; Brady ED; Song HA; Brechbiel MW
    J Med Chem; 2008 Jan; 51(1):118-25. PubMed ID: 18062661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
    Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
    Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
    Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
    Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
    J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
    Giblin MF; Sieckman GL; Shelton TD; Hoffman TJ; Forte LR; Volkert WA
    Nucl Med Biol; 2006 May; 33(4):481-8. PubMed ID: 16720239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals.
    Cai H; Li Z; Huang CW; Park R; Shahinian AH; Conti PS
    Nucl Med Biol; 2010 Jan; 37(1):57-65. PubMed ID: 20122669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3.
    Mohsin H; Fitzsimmons J; Shelton T; Hoffman TJ; Cutler CS; Lewis MR; Athey PS; Gulyas G; Kiefer GE; Frank RK; Simon J; Lever SZ; Jurisson SS
    Nucl Med Biol; 2007 Jul; 34(5):493-502. PubMed ID: 17591549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
    de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.